Tristel (LSE:TSTL), the infection prevention specialist, is approaching its full-year results with a positive trading backdrop already flagged to the market. In a trading update dated 22 July 2026 covering its financial year to 30 June 2026, the company reported Revenue up 10% to £51.1 million and profit growth of 14%. The group has since issued a notice of results setting out its reporting timetable, making it one of the healthcare names on the FTSE AIM All Share index that investors are watching closely this autumn.
What the Company Does
Tristel develops and manufactures infection prevention products based on its proprietary chlorine dioxide chemistry. Its main market is the decontamination of reusable medical devices that cannot be sterilised by heat, such as ultrasound probes and endoscopes, which are used in hospitals and clinics. The company also supplies products for surface disinfection and for other markets, and it sells internationally through its own subsidiaries and distribution partners. A long-standing strategic aim has been to expand in North America, where regulatory approval for its high-level disinfection products opened a large potential market.
Latest Developments
The July 2026 full-year trading update was the most significant recent announcement. Tristel flagged profit ahead of market expectations, with continued growth and the group remaining Debt free. Business Weekly also commented that Tristel had added further to its cash pile while still targeting strong growth in the United States.
Earlier, Tristel published its half-year report on 2 March 2026. Separately, the group delivered double-digit revenue growth and a stronger cash position ahead of a transition in its chief executive role. During the year the group also issued several announcements relating to the exercise of employee share Options and updates to total voting rights, which are routine for a company with share-based incentive schemes.
Financial and Dividend Picture
The headline figures from the trading update, revenue of £51.1 million and profit growth of 14%, indicate that margins improved as sales grew. Tristel has a record of paying dividends and maintaining a net cash Balance Sheet with no bank debt. The final dividend for the year and detailed cash figures will be confirmed in the full results; last year's final results were released on 13 October 2025, offering a guide to the likely timing.
Sector and Index Context
Demand for medical device decontamination is supported by hospital infection control standards and by growth in diagnostic procedures such as ultrasound. Tristel competes with alternative technologies, including automated reprocessing systems and other chemical disinfectants. On the FTSE AIM All Share Index, Tristel is among the more established and profitable healthcare constituents, distinguishing it from the many earlier-stage life sciences companies on the market.
Key Risks
Risks include the pace of adoption in the United States, which requires hospitals to change established practices; competition from larger infection prevention groups; regulatory changes affecting product approvals; currency movements given significant overseas sales; and execution risk as Leadership changes take effect. The shares can also be sensitive to any shortfall against market expectations.
What to Watch Next
The immediate focus will be the full-year results, including the final dividend, cash position and commentary on current trading. Investors will also look for updates on progress in North America, the leadership transition and how the new chief executive frames priorities, and any guidance for the 2027 financial year.






Please wait processing your request...